Deferasirox Treatment Interruption in a Transfusion-Requiring Myelodysplastic Patient Led to Loss of Erythroid Response

Publisher： Karger

E-ISSN： 1421-9662|124|1|46-48

ISSN： 0001-5792

Source： Acta Haematologica, Vol.124, Iss.1, 2010-07, pp. : 46-48

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Early Deferasirox Treatment in a Patient with Myelodysplastic Syndrome Results in a Long-Term Reduction in Transfusion Requirements

By  

Acta Haematologica, Vol. 121, Iss. 1, 2009-03 ,pp. : 19-20

Karger

Access to resources Recommend Favorite

Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis

By  

Acta Haematologica, Vol. 120, Iss. 2, 2008-10 ,pp. : 70-74

Karger

Access to resources Recommend Favorite

Loss of Transfusion Dependency Following Deferasirox Treatment of Iron Overload in a Woman with Myelofibrosis and Spherocytosis - a Case Report

By  

Oncology Research and Treatment, Vol. 36, Iss. 4, 2013-03 ,pp. : 205-208

Karger

Access to resources Recommend Favorite

Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox

By  

Oncology Research and Treatment, Vol. 39, Iss. 6, 2016-05 ,pp. : 384-387

Karger

Access to resources Recommend Favorite

Dramatic erythroid response to low‐dose thalidomide in two patients with transfusion independent thalassemia and severe post‐transfusional alloimmune hemolysis

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : E141-E141

John Wiley & Sons Inc

Access to resources Recommend Favorite